Current Cardiovascular Risk Reports

, Volume 1, Issue 4, pp 303–309

Low-molecular-weight heparin use in acute coronary syndromes and percutaneous coronary interventions: An update

  • Jeffrey J. Link
  • John J. Warner
  • James A. de Lemos
Article
  • 15 Downloads

Abstract

Based on important studies published in the past year, the role of low-molecular-weight heparin in acute coronary syndromes and percutaneous coronary interventions has continued to evolve. For patients with non-ST-elevation acute coronary syndromes, several alternatives to enoxaparin have been introduced, including fondaparinux and bivalirudin. In patients with ST-elevation myocardial infarction, recent studies have demonstrated a clear mortality benefit from adjunctive antithrombin therapy and the superiority of a prolonged course of enoxaparin over a standard duration of unfractionated heparin. Furthermore, recent data have demonstrated the safety of enoxaparin as an alternative to unfractionated heparin among patients undergoing percutaneous coronary interventions.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  • Jeffrey J. Link
  • John J. Warner
  • James A. de Lemos
    • 1
  1. 1.University of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations